Objective:To explore the effects of magnetic nanoparticles on the proliferation, activation, cytotoxicity, and differentiation of immune cells in tumor therapy, and to provide new therapeutic strategies for further improving the therapeutic effect of cellular immunity.Methods:Iron oxide magnetic nanoparticles (SPIONCitrate) were prepared and directly mixed with CD8(+) T cells and CAR-T cells to observe the effects of immune cell phenotype, proliferation, and killing effect on Raji-luc cells in both in vitro and in vivo experiments.Results:After passing through magnetic nanoparticles, the proportion of Tem (CD45RO(+)CD62L(-)) and Tcm (CD45RO(+)CD62L(+)) in CD8(+)T cells increased, and the proportion of Tcm (CD45RO(+)CD62L(+)) decreased, which improved the proliferation ability of CD8(+)T cells both in vivo and in vitro, and also enhanced the killing effect of CD19-CAR-T cells.Conclusion:Magnetic nanoparticles can directly alter the phenotype of immune cells, enhance their ability to proliferate and kill tumor cells.

Purpose: To map supraclavicular fossa-involved lymph nodes (SCF-LNs) in patients with nonmetastatic breast cancer, evalu-ate the coverage of widely adopted atlases, and propose modified borders for individualized regional irradiation. Methods and Materials: M0 patients with biopsy-proven SCF-LNs who were SCF treatment-naive were included. The SCF was spatially divided into subregions, with each node mapped on the original images. The geographic misses after the borders of multiple atlases were evaluated and factors affecting SCF-LNs' spread pattern were analyzed. Results: From 1998 to 2022, 209 patients with 1242 SCF-LNs were eligible. Patients had a median of 4 nodes. At least 537 nodes (43.2%) in 147 patients (70.3%) were lateral to the sternocleidomastoid muscle (SCM), and 403 nodes (32.4%) in 127 patients (60.8%) were dorsal to the anterior scalene muscle (ASM). In the 88 patients with <= 3 SCF-LNs, at least 66 nodes (39.1%) in 40 patients (45.5%) were lateral to the SCM, and 34 nodes (20.1%) in 29 patients (33.0%) were dorsal to the ASM. These nodes were not covered by the Radiation Therapy Oncology Group (RTOG) atlas and partly within the Radiotherapy Comparative Effectiveness atlas. One hundred four patients (49.8%) had 432 SCF-LNs (34.8%) beyond the upper border of the European Society for Radiotherapy and Oncology (ESTRO) atlas. In multivari-ate regression, nodal sizes were associated with wider spread in the primary group. Being triple-negative (TN) subtype was associated with less spread in the recurrent group. Situation-based clinical target volumes (CTVs) were theorized, in which for a sequential spread, the pos-terior border could be the posterior scalene muscle or even be more constringent; otherwise, it should touch the anterior trapezius surface. Conclusions: SCF-LNs tend to spread laterally and dorsally beyond the RTOG borders, even in M0 stages with <= 3 SCF-LNs. The ESTRO upper border does not guarantee coverage with multiple SCF-LNs. Nodal burden and non-TN types are predictive of wider dissemination. A situation-based CTV is possibly feasible. Deciphering the SCF-LN spread route is needed. (c) 2022 Published by Elsevier Inc.

目的 探讨长链非编码RNA T-box转录因子5反义RNA 1(LncRNA TBX5-AS1)对结直肠癌细胞生物学行为的影响及其可能作用机制.方法 实时荧光定量聚合酶链反应(qRT-PCR)法检测结直肠癌组织、癌旁组织中TBX5-AS1和miR-92a-3p的表达量.体外培养人结直肠癌细胞HCT116,分别将TBX5-AS1过表达载体(pcDNA-TBX5-AS1)及其对照空载体(pcDNA)、miR-92a-3p特异性寡核苷酸抑制剂(anti-miR-92a-3p)及其阴性对照(anti-miR-NC)、miR-92a-3p寡核苷酸模拟物(miR-92a-3p mmics)及阴性对照mimic NC序列(miR-NC)、pcDNA-TBX5-AS1与miR-92a-3p mimics转染至HCT116细胞.MTT法、平板克隆形成实验、划痕实验与Transwell小室实验分别检测细胞增殖、克隆形成、迁移及侵袭能力;双荧光素酶报告基因实验检测TBX5-AS1和miR-92a-3p的靶向关系.结果 与癌旁组织比较,结直肠癌组织中TBX5-AS1的表达量降低,miR-92a-3p的表达量升高,差异有统计学意义(P＜0.05).转染pcDNA-TBX5-AS1或转染anti-miR-92 a-3p后细胞活力降低,克隆形成数和侵袭细胞数减少,迁移距离缩短,差异均有统计学意义(P＜0.05).TBX5-AS1可靶向调控miR-92 a-3p;转染miR-92a-3p mmics后细胞活力升高,克隆形成数和侵袭细胞数增多,迁移距离增加,差异有统计学意义(P＜0.05).共转染pcDNA-TBX5-AS1与miR-92a-3p mmics能够逆转pcDNA-TBX5-AS1对HCT116细胞生物学行为的作用.结论 TBX5-AS1过表达可通过抑制miR-92a-3p的表达,减弱结直肠癌细胞增殖、克隆形成、迁移及侵袭能力.

目的 探讨长链非编码RNA Prader-Willi区域非蛋白质编码RNA 1(PWRN1)是否通过磷脂酰肌醇-3-激酶/丝氨酸苏氨酸蛋白激酶(PI3K/Akt)通路调控乳腺癌细胞增殖、侵袭和迁移过程.方法 采用实时荧光定量PCR(qPCR)检测正常乳腺上皮细胞MCF-10A和乳腺癌细胞(BT474、BT549、T47D、MCF7、MDA-MB-453、MDA-MB-231)的PWRN1水平.选择MDA-MB-231细胞并分为空白对照组(不进行转染)、阴性对照组(转染空载体pcDNA3.1)和PWRN1过表达组(转染过表达载体pcDNA3.1-PWRN1).细胞计数法(CCK-8)、划痕愈合实验和Transwell小室实验分别检测细胞增殖、迁移和侵袭能力.Western blotting和qPCR检测Snail、基质金属蛋白酶9(MMP-9)、磷酸化磷脂酰肌醇3-激酶(p-PI3K)和磷酸化丝氨酸苏氨酸蛋白激酶1(p-Akt1)的水平.结果 乳腺癌细胞的PWRN1水平均低于MCF-10A细胞,差异有统计学意义(P<0.05).与空白对照组和阴性对照组相比,PWRN1过表达组MDA-MB-231细胞的增殖活力(48 h和72 h)减弱、划痕愈合率和穿膜细胞数较少,且Snail、MMP-9、p-Akt1和p-PI3K水平降低,上述差异均有统计学意义(P<0.05).空白对照组和阴性对照组上述指标的差异无统计学意义(P>0.05).结论 PWRN1可能通过减弱PI3K/Akt信号通路活化来抑制乳腺癌细胞的增殖、侵袭和迁移,PWRN1/PI3K/Akt轴有作为乳腺癌防治靶点的潜能.

[目的]探讨LncRNA FAM230B对结直肠癌细胞增殖及转移的影响及其可能作用机制.[方法]体外培养正常人结肠上皮细胞FHC和人结直肠癌细胞系SW480、SW620、HCT116,qRT-PCR法与Western blotting法分别检测LncRNA FAM230B、IL6R mRNA及蛋白表达量;以SW480细胞为研究对象,根据转染物不同分为以下几组:NC组、si-NC组、si-LncRNA FAM230B组、pcDNA组、pcDNA-LncRNA FAM230B组、pcDNA+ si-LncRNA FAM230B组、pcDNA-IL6R+ si-LncRNA FAM230B组;MTT、Transwell小室实验分别检测细胞增殖、迁移及侵袭;Western blotting法检测原癌基因(C-myc)、基质金属蛋白酶2(matrix metalloproteinases2,MMP2)、基质金属蛋白酶9(matrix metalloproteinases9,MMP9)蛋白表达量.[结果]与FHC细胞比较,SW480、SW620、HCT116细胞中LncRNA FAM230B和IL6R的表达量升高(P＜0.05);与si-NC组比较,si-LncRNA FAM230B组细胞活力降低(P＜0.05),迁移及侵袭细胞数减少(P＜0.05),C-myc、MMP2、MMP9蛋白水平降低(P＜0.05),IL6R的表达量降低(P＜0.05);与pcDNA组比较,pcDNA-LncRNA FAM230B组细胞活力升高(P＜0.05),迁移及侵袭细胞数增多(P＜0.05),C-myc、MMP2、MMP9蛋白水平升高(P＜0.05),IL6R的表达量升高(P＜0.05);与pcDNA+si-LncRNA FAM230B组比较,pcDNA-IL6R+si-LncRNA FAM230B组细胞活力升高(P＜0.05),迁移及侵袭细胞数增多(P＜0.05),C-myc、MMP2、MMP9蛋白水平升高(P＜0.05).[结论]干扰LncRNA FAM230B表达可通过抑制IL6R的表达而减弱结直肠癌细胞增殖及转移能力.

目的 探讨不同性别老年人高尿酸血症与代谢综合征(MS)的关系.方法 选择2018年4月1日～11月30日青岛市市南区八大湖街道巢湖路社区卫生服务中心体检老年人1757例,男性712例,女性1045例,根据血尿酸水平分为高尿酸血症组377例,正常尿酸组1380例.采用统一调查表,测量身高、体质量、血压,检测生化指标,分析不同性别高尿酸血症和MS患病率.结果 高尿酸血症患病率21.5％,MS患病率28.5％,其中男性28.1％,女性28.7％.高尿酸血症组体质量指数、MS、高血压、收缩压、舒张压、TC、TG和LDL-C水平明显高于正常尿酸组,HDL-C水平低于正常尿酸组(P＜0.05,P＜0.01).男性和女性高尿酸血症患病率均随MS组分数量增加而升高(8.3％ vs 17.0％ vs 23.4％ vs 25.3％ vs 23.3％,P=0.001;8.9％ vs 14.7％ vs 21.3％ vs 33.6％ vs 38.5％,P=0.000).logistic回归分析显示,调整年龄、吸烟和饮酒因素后,老年男性超重/肥胖、高脂血症为高尿酸血症发生的独立危险因素,高血糖为高尿酸血症发生的保护因素(P＜0.05,P＜0.01);老年女性MS、超重/肥胖、高血压、高脂血症为高尿酸发生的独立危险因素(P＜0.05,P＜0.01).结论 青岛市市南区老年人高尿酸血症和MS患病率较高,老年女性高尿酸血症与MS存在相关性.

目的 探讨盐酸埃克替尼治疗晚期复发非小细胞肺癌患者的临床疗效.方法 选取2015年4月至2017年9月间青岛市肿瘤医院收治的68例晚期复发非小细胞肺癌患者,采用随机数表法分为观察组和对照组,每组34例.对照组患者采用常规临床化疗治疗,观察组患者在对照组基础上加用盐酸埃克替尼片联合治疗,比较两组患者的临床有效率.结果 观察组患者临床有效率为73.5％,高于对照组的61.8％,差异有统计学意义(P＜0.05).两组患者不良反应发生情况比较,差异无统计学意义(P＞0.05).结论 盐酸埃克替尼治疗晚期复发非小细胞肺癌患者,可提高临床疗效,有一定的安全性,值得临床运用.

目的 甲状腺癌患者在术后的放疗价值分析.方法 甲状腺癌术后仍有癌变组织的患者40例,在进行放疗后,观察患者后续的生存率情况.结果 在经过放疗后,患者在3年、5年、10年的生存率分别是92.5%、70.0%、42.5%.结论 甲状腺癌患者经过手术后对其病情有很大治疗效果,术后的残余癌可通过放疗进行缓解,但缓解效果受到病理类型,放射量的多少和癌变肿瘤的大小所影响,具体情况还需具体分析.

目的:探讨适形调强放疗联合多西他赛与顺铂化疗(TP方案)治疗晚期食管癌的临床疗效及不良反应.方法:将68例晚期食管癌患者随机分为两组,即单纯接受调强放疗治疗的放疗组和接受联合调强放疗及TP化疗的联合组,每组34例.对比两组临床治疗效果.结果:联合组治疗有效率为76.64％,优于放疗组的44.11％,差异有统计学意义(P＜0.05);两组治疗放射性肺炎、乏力并发症发生率比较差异无统计学意义(P＞0.05).两组恶心呕吐、骨髓抑制并发症发生率比较差异有统计学意义(P＜0.05).联合组随访3年的死亡率及肿瘤转移率分别为64.70％及14.71％,明显低于放疗组的88.23％及35.29％(均P＜0.05).结论:对晚期食管癌患者行调强放疗联合TP方案化疗可有效地提高临床治疗效果和改善患者的预后.

目的:探讨分析对甲状腺癌术后残余癌患者进行放疗后的临床效果. 方法:选定80例甲状腺癌术后确诊为残余癌患者作为研究对象,所有被选取患者均使用X线或者辅助电子线放射治疗. 观察治疗后患者的临床疗效及生存情况. 结果:甲状腺癌术后残余癌患者经治疗后,未分化癌、低分化癌、高分化癌3年及5年生存率逐渐升高(P<0. 05),照射剂量在70 Gy以上的患者3年及5年生存率高于其他照射剂量患者(P<0. 05),统计学差异明显;1年生存率均无显著差异(P>0. 05). 镜下残余患者1(100. 00%)、3(100. 00%)、5(80. 00%)年生存率均高于肉眼残余患者(86. 67%、70. 00%、50. 00%),P<0. 05,统计学差异显著. 结论:甲状腺癌术后残余癌采用放疗治疗能够有效延长患者生存期限,放疗效果与病理分型、残余量及放疗照射剂量有密切关联.

目的:探讨晚期食管癌放疗联合化疗与放疗联合靶向治疗的安全性及有效性.方法:随机选取晚期食管癌患者80例,分为治疗组和对照组,各40例.治疗组予放疗联合盐酸厄洛替尼治疗,对照组予放疗联合化疗,比较两组患者治疗的不良反应、死亡率、有效率、生存率.结果:治疗组和对照组消化道反应发生率分别为2.5％和92.5％,骨髓抑制发生率分别为32.5％和47.5％,放射性食管炎发生率分别为90％和95％,放射性肺炎发生率分别为5％和7.5％,皮疹发生率分别为62.5％和7.5％.治疗组完全缓解(CR)+部分缓解(PR)38例,总有效率95％,高于对照组总有效率87.5％,但差异无统计学意义(P＞0.05).治疗组和对照组中位生存期分别为(21.3±1.7)、(15.6±1.3)个月,1年生存率分别为75％、67.5％,2年生存率分别为52.5％、47.5％,3年生存率分别为37.5％、17.5％.两组患者中位生存时间比较治疗组优于对照组(P＜0.05);两组患者1年生存率比较差异无统计学意义(P＞0.05),2、3年生存率比较治疗组优于对照组(P＜0.05).结论:对晚期食管癌行放疗联合靶向治疗安全性高,毒副作用小,患者中位生存期长,值得临床推广.

Objective To investigate the clinical curative effect of the patients using beta ray radiotherapy for postoperative ocular malignant tumor. Methods From August 2011 ~ February 2013 34 cases of ocular malignant tumor patients after operation in our hospital , according to the different treatment methods were divided into observation group (17 cases, beta ray radiotherapy), control group (17 cases, conventional radiotherapy), clinical therapeutic effects were compared between the two groups. Results The observation group total effective rate 94.1%, the total rate of adverse effects in 11.8%, control group total effective rate 58.8%, the total rate of adverse effects in 47%, data were compared between the two groups, the difference was statistically significant (P<0.05). Conclusion Ocular malignant tumor patients after application of beta ray radiotherapy, curative effect, safe and reliable, can reduce the incidence of adverse reactions, help patients better rehabilitation.

Objective:To study the action of paclitaxel nanoparticle(TAX - NLC)on KB cells. Methods:F - ac-tin and apoptosis of KB cells after being exposed to TAX - NLC were observed by laser confocal microscopy. Cytomor-phology of KB cells after being exposed to TAX - NLC was observed by light microscope. Results:After KB cells were exposed to TAX - NLC,F - actin of KB cells was gathered into a mass,punctate,the microfilament function was inhib-ited. The apoptosis of KB cells were induced by TAX - NLC. Many multinucleated cells of KB cells were induced by TAX - NLC. Conclusion:TAX - NLC destroyed microfilament function,induced apoptosis and multinucleated cells, finally tumor cells were killed.

目的:探究调强放疗(IMRT)联合厄洛替尼治疗晚期食管癌的疗效和安全性,为临床晚期食管癌的治疗提供参考.方法:选择晚期食管癌患者87例作为研究对象,对照组41例采用单纯IMRT,试验组46例采用IMRT配合厄洛替尼治疗,观察分析两组患者的临床疗效和不良反应发生情况,并随访第1、2年的生存状况.结果:试验组患者有效率(86.96％)明显高于对照组(43.90％)(x2=18.083,P＜0.05),放射性食管炎、口腔黏膜炎、放射性肺炎、骨髓抑制、消化道反应等不良反应发生率两组间差异均有统计学意义(P＜0.05),虽然第1、2年的生存率对照组(68.29％、48.78％)略高于试验组(65.22％、47.83％),但两组间生存状况的差异无统计学意义(x2 =0.092、x2=0.008,P=0.761、P=0.929).结论:调强放疗联合厄洛替尼对晚期食管癌治疗效果显著,且并发症少,临床可以作为晚期食管癌治疗的一种参考方法.

Objective:To compare the inhibitory effect of paclitaxel lipid nanoparticles(TAX-NLC)on KB,SKOV3 cells. Method:The affection of TAX-NLC on Ca2+in KB,SKOV3 cells by using Laser confocal microscope were observed.MTT method was used to determine the inhibition rate of TAX-NLC action in KB,SKOV3 cell.The cell morphological changes of TAX-NLC role in KB,SKOV3 cells were observed by Laser confocal microscope.Result:After the TAX-NLC acting on KB,SKOV3 cells,the concentration of Ca2+of KB cells was higher than that of SKOV3 cells.And the inhibition rate of KB cell was higher than that of SKOV3 cells,the production of KB multinucleated cells was more than that of SKOV3 cells.Conclusion:TAX-NLC is more sensitive to KB cells,Ca2+concentration,the inhibition rate,multinucleated cells are closely associated.

Objective To analyze curative effect and adverse reactions of icotinib combined with whole brain radiotherapy in the treatment of senile lung adenocarcinoma with brain metastases patients. Methods A total of 57 senile lung adenocarcinoma with brain metastases patients, without receiving chemotherapy, were divided by different treatment methods into targeted combined radiotherapy group (27 cases) and single radiotherapy group (30 cases). Effective rate, median survival time, survivorship curve, and adverse reactions of the two groups were observed and compared. Results There were statistically significant differences of effective rate (81.5%VS 40.0%) and disease control rate (96.3%VS 73.3%) between the targeted combined radiotherapy group and the single radiotherapy group (P<0.05). The targeted combined radiotherapy group had median survival time as 11 months and 1 year survival rate as 51.9%, and those in the single radiotherapy group were 7 months and 23.3%. The difference of 1 year survival rate between the two groups had statistical significance (P=0.02<0.05). Main adverse reactions in the targeted combined radiotherapy group was rash, with the occurrence rate as 63.0%. There were 2 cases with grade 4 rash, and they received continuous targeted drug by oral administration after symptomatic treatment. Conclusion Implement of icotinib combined with radiotherapy provides good curative effect and few adverse reactions in treating senile lung adenocarcinoma with brain metastases patients. It is worth clinical promotion and application.

目的 研究鼻咽癌患者放射治疗后的颈髓损伤状况.方法 选择2013年1月至2014年10月间青岛市肿瘤医院收治的鼻咽癌放疗后出现放射性颈髓损伤(RICCI)的30例患者为研究组,以同期门诊随访的鼻咽癌放疗后经影像学检查及体格检查未发现RICCI的31例患者作为对照组,对两组患者进行MRI检查.结果 放疗前两组患者感觉运动评分差异无统计学意义(P＞0.05);放疗后研究组患者感觉运动评分低于对照组,差异有统计学意义(P＜0.05).研究组患者颈髓囊变的长度、横截面、体积明显大于对照组,美国脊柱损伤学会(ASIA)评分小于对照组(P＜0.05).放疗后,研究组B、C等级患者数明显高于对照组,D、E等级患者数低于对照组,差异均有统计学意义(均P＜0.05).结论 鼻咽癌放疗可诱发RICCI,对患者的感觉运动、颈髓囊变的长度、横截面、体积均具有负面作用,加重患者的颈髓神经损伤,引起Frankle等级变化.

<正>放射性口腔黏膜炎是头颈部肿瘤放疗的常见并发症,轻者使患者疼痛,影响进食,降低生活质量,重者使放疗无法进行,影响治疗效果,因此放射性口腔黏膜炎的治疗显得尤为重要。我们采用金因肽治疗放射性口腔黏膜炎取得较好的疗效,现总结

OBJECTIVE: To evaluate the effect of intensity modulated radiation therapy(IMRT) combined with Docetaxl chemotherapy for locally late stage non-small cell lung cancer.METHODS:Totally 65 NSCLC patients were involved.Group A consisted of 35 patients,treated with IMRT combined Docetaxel and Cisplatin chemotherapy,and after radiation therapy,they received Docetaxel and Cisplatin chemotherapy for two therapy cycles.Group B consisted of 30 patients,receiving IMRT,then Docetaxel and Cisplatin chemotherapy for 4-6 therapy cycle.RESULTS: The overall response rate(CR+PR)was 82.9% in Group A,and 60.0% in Group B.The overall response rate of Group A was higher than Group A(P=0.04);The one-year and two-year survival rate of Group A were 77.1% and 48.6%,and that of Group B were 73.3% and 43.3% respectively.There were no significant differences between Group A and Group B in one-year and two-year survival rate(P=0.63).The incidence of leucopenia was 77.1% in Group A,and 53.3% in Group B(P=0.123);The incidence of radiation-induced esophagitis was 65.7% in Group A,and 53.3% in Group B(P=0.582).The incidence of radiation-induced pulmonitis was 45.7% in Group A,and 40.0% in Group B(P=0.898).CONCLUSION: The short-term effect of intensity modulated radiation therapy(IMRT) combined with Docetaxl is better than sequential radiotherapy and chemotherapy,while there are no significant differences in adverse reactions between the two treatment.

The objective of this study was to compare the efficacy of different radiation options in non-small cell lung cancer(NSCLC) patients with brain metastasis,and study its prognostic factor.Retrospective analysis of 97 NSCLC patients with brain metastases was carried out.Group A including 23 cases received whole brain radiotherapy 30 Gy/10 f while Group B 45 cases receiving whole brain radiotherapy 40 Gy/20 f.Group C including 29 patients received whole brain radiotherapy 40 Gy/20 f,and then increased by 10 Gy/5 f to partially reduced field.The median survival time was 8.7 months,and 1-year local control rate was 23% in Group A while in Group B 8.8 months and 63%,in Group C 9.2 months,and 84% respectively.There was no significant difference in median survival time among three groups(P0.05).However,the 1-year local control rate of Group C was significantly higher than that of Group A.Univariate analysis showed that metastasis outside of the brain and the number of metastases in the brain were the prognostic factors.Multivariate Cox model analysis showed that metastasis outside of the brain was independent prognostic factor.In conclusion,in NSCLC patients with brain metastases,both metastasis outside of the brain and number of metastases in the brain have correlation with prognosis.Metastasis outside of the brain is independent prognostic factor.